Hess S - Search Results

1

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hügl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Cappato R, et al. Among authors: hess s. Eur Heart J. 2015 Jul 21;36(28):1805-11. doi: 10.1093/eurheartj/ehv177. Epub 2015 May 14. Eur Heart J. 2015. PMID: 25975659 Free PMC article. Clinical Trial.

2

Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.

Naccarelli GV, Cappato R, Hohnloser SH, Marchlinski FE, Wilber DJ, Xiang J, Ma C, Hess S, Davies DW, Fields LE, Natale A; VENTURE-AF Investigators. Naccarelli GV, et al. Among authors: hess s. J Interv Card Electrophysiol. 2014 Nov;41(2):107-16. doi: 10.1007/s10840-014-9924-9. Epub 2014 Jul 9. J Interv Card Electrophysiol. 2014. PMID: 25005452 Clinical Trial.

3

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG; XANTUS Investigators. Camm AJ, et al. Among authors: hess s. Eur Heart J. 2016 Apr 7;37(14):1145-53. doi: 10.1093/eurheartj/ehv466. Epub 2015 Sep 1. Eur Heart J. 2016. PMID: 26330425 Free PMC article.

4

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.

Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; ESC Scientific Document Group. Heidbuchel H, et al. Eur Heart J. 2017 Jul 14;38(27):2137-2149. doi: 10.1093/eurheartj/ehw058. Eur Heart J. 2017. PMID: 27282612 Free PMC article.

5

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ. Amarenco P, et al. Among authors: hess s. Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 30423165

6

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.

Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ; XANTUS Investigators*. Kirchhof P, et al. Among authors: hess s. J Am Heart Assoc. 2020 Mar 3;9(5):e009530. doi: 10.1161/JAHA.118.009530. Epub 2020 Feb 21. J Am Heart Assoc. 2020. PMID: 32079476 Free PMC article.

7

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators. Camm AJ, et al. Among authors: hess s. Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127. Europace. 2018. PMID: 29016755

8

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG. Camm AJ, et al. Among authors: hess s. Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160. Europace. 2019. PMID: 30052894

9

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, van Eickels M, Turpie AG. Camm AJ, et al. Among authors: hess s. Vasc Health Risk Manag. 2014 Jul 17;10:425-34. doi: 10.2147/VHRM.S63298. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 25083135 Free PMC article. Clinical Trial.

10

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.

Coleman CI, Haas S, Turpie AG, Kuhls S, Hess S, Evers T, Amarenco P, Kirchhof P, Camm AJ; XANTUS Investigators. Coleman CI, et al. Among authors: hess s. Clin Cardiol. 2016 Oct;39(10):565-569. doi: 10.1002/clc.22565. Epub 2016 Jun 30. Clin Cardiol. 2016. PMID: 27362695 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,199 results

Search Page